MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., an antibody discovery and development company, will present data from its Phase 1 study of XmAb®2513, an anti-CD30 Fc engineered humanized monoclonal antibody for the treatment of patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma, on June 1 in a poster session at the American Society of Clinical Oncology Annual Meeting being held at the Orange County Convention Center in Orlando, Florida.
